Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 19/20 | 1.00 |
| ▸ | EDNRB | P24530 | 18/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | TSPO | P30536 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14380520 | 0.93 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380527 | 0.92 | EDNRA (0.85) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380528 | 0.91 | EDNRB (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL17582648 | 0.90 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL31266904 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5101990 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5500351 | 0.88 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| Macitentan SCHEMBL1445625 | 0.88 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| Macitentan SCHEMBL29378853 | 0.88 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL8354846 | 0.87 | EDNRA (0.85) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938244-B2 | Process for manufacturing pyrimidine sulfamide derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-10 | — | — | US | disclosed |
| US-20160368882-A1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-12-22 | — | — | US | disclosed |
| US-8324232-B2 | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-06-07 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368882-A1 | PROCESS FOR MANUFACTURING PYRIMIDINE SULFAMIDE DERIVATIVES | HAT1, SF1, SF3B5 | EDNRA 4588/4885EDNRB 3396/4885SLC6A2 1727/4885 |
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | EDNRB, EDNRA, TBXA2R | EDNRA 2/4885EDNRB 1/4885SLC6A2 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.